Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
NCT Number: NCT00446420
Our hypothesis is that adding midazolam and/or fentanyl to propofol sedation for elective outpatient colonoscopy increases cognitive impairment at hospital discharge without improving intraoperative conditions or reducing intraoperative side-effects.
200 healthy patients aged 18 years or older will be randomised to receive propofol or propofol plus midazolam and/or fentanyl. Cognitive impairment will be tested at hospital discharge using Cogstate computerised testing software.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Parkville, Victoria, 3050, Australia
A great variety of drug combinations are administered to patients having elective outpatient colonoscopy. In addition, as patients are going home, some may have residual cognitive deficits that making leaving the hospital unsafe. This study aims to find drugs combinations that are associated with the least cognitive impairment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
All drugs administered in doses according to anaesthetists' discretion during sedation for colonoscopy
Other names: Diprivan, Sublimase, Versed
Time frame: Before discharge from daycare facility
Time frame: Before discharge from daycare facility
Melbourne Health
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07711834
Cognition Disorders, Cognitive Dysfunction
Harbin, Heilongjiang, China
View Trial DetailsNCT07396779
Behavior, Behavioral Symptoms
Istanbul, Beykoz, Turkey (Türkiye)
View Trial DetailsNCT06186102
Arterial Occlusive Diseases, Arteriosclerosis
Aarhus, Jutland, Denmark
View Trial DetailsNCT03121209
Arterial Occlusive Diseases, Brain Diseases
Birmingham, Alabama, United States
View Trial Details